{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Proportion of patients with best recorded response as assessed using RECIST v1.1 of complete or partial response","groups":[{"description":"Patients will receive an initial dose of pembrolizumab in week 1 dosed at 200 mg. They will then receive SBRT dosed at 30 Gy in 3 fractions (#) alternate days in week 3. Treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.\n\nPembrolizumab: Pembrolizumab will be continued dosed at 200 mg given every 3 weeks\n\nDrug: Pembrolizumab Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.\n\nStereotactic Body Radiotherapy (SBRT): Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)","id":"OG000","title":"Initial Safety Cohort"},{"description":"An additional 12 patients will be recruited for this cohort. Patients will receive an initial dose of pembrolizumab at 200 mg in week 1. This will be followed in by SBRT dosed at 30 Gy in 3 fractions (#) alternate days in week 3. Treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.\n\nPembrolizumab: Pembrolizumab will be continued dosed at 200 mg given every 3 weeks\n\nDrug: Pembrolizumab Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.\n\nStereotactic Body Radiotherapy (SBRT): Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)","id":"OG001","title":"Expansion Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients who commenced trial treatment and who were assessed at least once for response","reportingStatus":"POSTED","timeFrame":"Response assessed from start of pembrolizumab, every 9 weeks for the first 6 months, then every 12 weeks thereafter, until the first instance of documented disease progression, start of new anti-cancer treatment, death or end of study (24 months)","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}